Sunshine Biopharma files draft information statement
SBFM•Sunshine Biopharma filed a draft information statement outlining shareholder authorization for discounted share issuance exceeding 20% of its outstanding common stock. The authorization covers Series D Warrants issued in an offering that raised approximately $6 million in gross proceeds.
1. Warrant adjustments
The October 13, 2026, authorization covers adjustments to Series D Warrant exercise prices and proportional changes to underlying shares following share combinations. Those adjustments could reduce the initial $0.66 exercise price to a minimum of $0.275, with the number of issuable shares increasing proportionately. Shareholders also authorized the board to voluntarily reduce the warrants’ exercise prices.
